Santen Pharmaceutical
Basic Information
- Stock Code
- 4536
- Industry
- Pharmaceuticals
- Category Detail
- Biotechnology & Pharmaceuticals
- Prefecture
- Osaka Prefecture
- Establishment Year
- July 1925
- Listing Year
- November 1963
- Official Website
- https://www.santen.co.jp/
- TSE Information
- TSE Information
- Yahoo! Finance
- Yahoo! Finance
- Other Companies
- Kyowa Kirin, Takeda Pharmaceutical, Astellas Pharma, Sumitomo Pharma, Shionogi, Nippon Shinyaku, Chugai Pharmaceutical, Eisai, Rohto Pharmaceutical, Ono Pharmaceutical, Hisamitsu Pharmaceutical, Kissei Pharmaceutical, Daiichi Sankyo, Otsuka Holdings
Overview
Santen Pharmaceutical is a leading Japanese company specializing in ophthalmic pharmaceuticals founded in 1925, boasting the No. 1 share in domestic prescription eye drops and advancing market expansion through global deployment.
Current Situation
Santen Pharmaceutical recorded consolidated sales of approximately 266.3 billion yen and operating profit of approximately 35.9 billion yen in the fiscal year ended March 2022, maintaining a solid financial base. In the core ophthalmic pharmaceuticals market, it has established the top share in Japan for prescription eye drops and the No. 2 position in over-the-counter eye drops. In recent years, it has successfully expanded sales channels in the European market through collaboration with U.S. Merck, accelerating its global growth strategy. In product development, it addresses market needs with the launch of over-the-counter eye drops with new ingredients and myopia suppression drugs, promoting innovation. It also focuses on reducing environmental impact and sustainable management, positioning sustainability at the core of its corporate strategy. Looking ahead, it aims to enhance the overseas sales ratio and expand R&D investment toward 2030 by leveraging digital technologies and developing emerging markets.
Trivia
Interesting Facts
- Established in 1925, it is a venerable Japanese pharmaceutical company that grew specializing in ophthalmic drugs.
- Holds the No. 1 share in Japan's prescription eye drop market.
- Experienced litigation in 1998 over the 'Sante' trademark with a mail-order health food company.
- Developed the world's first plastic container eye drops in 1962.
- Has a track record of selling Evangelion collaboration eye drop models.
- Refreshed corporate slogan to 'Imagine Your Happiness' in 2020.
- Launched 'Hialain S' eye drops with prescription-level hyaluronic acid in 2020.
- The community brand 'Sante' means 'health' in French.
- Emergency product recall response was praised as a model of corporate crisis management.
- Has numerous affiliates and bases in Japan and overseas, promoting global expansion.
- Conducts CM campaigns tied up with numerous celebrities and anime.
- High competitiveness in both OTC and prescription eye drops within the industry.
- 'Sante FX' OTC eye drops have strong popularity among youth.
- Expanding share in Europe by leveraging U.S. Merck's distribution channels.
- Develops specialized products such as allergy-specific and myopia treatment eye drops.
Hidden Connections
- Accelerating global expansion by utilizing major pharmaceutical Merck's European distribution channels.
- Boosted recognition among youth through product collaboration with Neon Genesis Evangelion anime.
- Ongoing market share battle with Rohto Pharmaceutical since the 1990s.
- Employs numerous female voice actors and celebrities as image characters.
- Developed plastic containers widely used as industry standard technology.
- Implemented rapid product recall in response to 2000 foreign object contamination extortion incident as safety measure.
- Overseas subsidiaries deployed in the U.S., Europe, and Asia, addressing local market needs.
- Company name origin based on words from the Confucian classic 'Doctrine of the Mean'.
Future Outlook
Growth Drivers
- Expansion of ophthalmology medical demand due to aging population
- Market expansion for new treatments like myopia suppression drugs
- Distribution expansion and product recognition improvement in overseas markets
- Pharmaceutical development efficiency through digital technology utilization
- Brand value enhancement through sustainability initiatives
- Growth in allergy disease market
- Increasing needs for functional diversification in OTC eye drops
- Strengthened infection prevention and ophthalmology-related safety measures
- Response to personalized medicine
- Rising demand for eco-packaging and environmentally considerate products
- Differentiated product development leveraging new ingredients and technologies
- Strengthened collaboration with global pharmaceutical companies
Strategic Goals
- Achieve 70% global sales ratio
- Maintain R&D expense to sales ratio above 8%
- Achieve carbon neutrality
- Realize launch of 10 or more new products
- Secure top industry ranking in sustainability evaluations
- High functionalization and diversification of product lineup
- Full introduction of digital clinical trials
- Expansion of regional medical collaboration and CSR activities
- Strengthen presence in Asian markets
- Build sustainable supply chains
Business Segments
Prescription Eye Drop Manufacturing
- Overview
- Conducts research, manufacturing, and stable supply of advanced prescription eye drops specialized for ophthalmology.
- Competitiveness
- Domestic top share in pharmaceutical technology and global sales network
- Customers
-
- Hospitals
- Clinics
- Ophthalmologists
- Pharmacies
- Products
-
- Diquas
- Timoptol
- Rescula
- Tapcom Combination Eye Drops
- Hialain
Over-the-Counter Pharmaceutical Manufacturing
- Overview
- Manufacturing and sales of eye drops for general consumers. Product lineup addressing a wide range of needs.
- Competitiveness
- High-function formulations and brand recognition
- Customers
-
- Drugstore chains
- Supermarkets
- Convenience stores
- Pharmacies
- Mail order
- Products
-
- Sante FX series
- Sante Medical series
- Hialain S
Overseas Business & Sales Network
- Overview
- Pharmaceutical sales and marketing in overseas markets leveraging international partnerships.
- Competitiveness
- Distribution expansion power through partner companies
- Customers
-
- Overseas medical institutions
- Overseas pharmacies
- Overseas drug chains
- Pharmaceutical wholesalers
- Products
-
- Myopia-suppressing eye drops for Europe
- Eye drop products for North America and Asia
R&D Services
- Overview
- Provides research and development support for ophthalmic-related pharmaceuticals using proprietary technologies.
- Competitiveness
- Innovative technologies from a highly specialized research team
- Customers
-
- Pharmaceutical companies
- University research institutions
- Public research institutes
- Products
-
- New ingredient development for ophthalmic drugs
- Clinical trial support services
Pharmaceutical Manufacturing Outsourcing
- Overview
- Provides eye drop manufacturing outsourcing services with high quality control.
- Competitiveness
- Production facilities meeting prescription quality standards
- Customers
-
- Prescription pharmaceutical manufacturers
- Over-the-counter pharmaceutical manufacturers
- Products
-
- Eye drop manufacturing outsourcing
- Container molding and filling technology
Nutritional Supplement Manufacturing & Sales
- Overview
- Development and sales of functional foods supporting eye health.
- Competitiveness
- Product development based on scientific evidence
- Customers
-
- Drugstores
- Hospital shops
- Mail order businesses
- Products
-
- Sante Luteax series
- Functional foods
Formulation Technology Development
- Overview
- Develops technologies to improve convenience and environmental performance of eye drop formulations.
- Competitiveness
- Domestic first plastic container adoption technology
- Customers
-
- In-house products
- Partner pharmaceutical companies
- Products
-
- Plastic container eye drops
- Eco-packaging technology
Competitive Advantage
Strengths
- High expertise specialized in ophthalmic pharmaceuticals
- No. 1 domestic share in prescription eye drops
- Diversified distribution channels through global expansion
- Strong product development capabilities and diverse product lineup
- Market expansion power through international partnerships
- Long history and established brand strength
- Advanced eye drop formulation technology
- Abundant patents and intellectual property holdings
- Stable financial base
- Proactive sustainability initiatives
- Secured diverse sales channels
- Comprehensive domestic and international R&D bases
- Product safety management and crisis response capabilities
- Multi-language brand slogan deployment
- Robust customer service system
Competitive Advantages
- High technology and marketing strength due to specialization in ophthalmology
- Established market superiority in both prescription and OTC segments
- Utilization of European channels through partnership with overseas Merck
- Development of proprietary ingredients and high-function formulations in eye drops
- Strong domestic sales channels and brand recognition
- Competitiveness through multi-faceted product lineup
- Promotion of environmentally considerate manufacturing and eco-packaging
- Customer touchpoint expansion through both online and store sales
- Introduction of cutting-edge technologies in R&D
- Track record in risk management and crisis response
- Accumulated formulation technology from years of experience
- Rapid response to pharmaceutical regulations
- Market adaptability through sales subsidiaries in multiple regions
- Multi-language brand message deployment
- Enhanced product safety and quality assurance systems
Threats
- Intensifying international competition for myopia treatments
- Revenue pressure risk from drug price revisions
- Competition in new technologies and products from other pharmaceutical companies
- Overseas market fluctuations due to political and economic conditions
- Delays in approvals and distribution due to strengthened regulations
- Market share decline due to new entrants
- Increase in generics following patent expirations
- Revenue impact from exchange rate fluctuations
- Supply chain disruptions from novel infectious diseases
- Credit decline from product safety issues
- Rising prices of natural resources and raw materials
- Competitive decline from delays in digitalization response
Innovations
2020: Corporate name notation and slogan refresh
- Overview
- Unified corporate brand name to 'Santen' and refreshed slogan.
- Impact
- Improved global brand recognition and established unified brand image
2021: European marketing approval for myopia-suppressing eye drops
- Overview
- Newly developed myopia-suppressing eye drops obtained marketing approval in Europe.
- Impact
- New entry into European market with expected sales growth
2022: Transfer of anti-rheumatic drug business
- Overview
- Transferred anti-rheumatic drug business to advance ophthalmology-focused strategy.
- Impact
- Concentration of management resources and business efficiency
2023: Launch of Sante Medical Plus 12
- Overview
- Launched over-the-counter eye drop with enhanced vitamin E and additional formulation ingredients.
- Impact
- Strengthened product lineup and response to customer needs
2024: Strengthening clinical development using digital technologies
- Overview
- Improved new product development speed and clinical trial efficiency through AI introduction.
- Impact
- Shortened development lead time and enhanced competitiveness
Sustainability
- CO2 emission reductions in manufacturing processes
- Promotion of energy-saving equipment introduction
- Waste recycling rate improvement activities
- Expansion of eco-packaging material adoption
- Support for regional environmental conservation activities
- Strengthening supply chain sustainability
- Development of healthy and safe workplace environments
- Formulation of global human rights respect policy
- Promotion of employee diversity and inclusion
- Implementation of medical support programs for local communities